DocWire News Editors

DocwireNews

<h2 class="entry-title"><a href="https://www.docwirenews.com/cardiology/pacific-af-trial-asundexian-versus-apixaban-in-atrial-fibrillation/">PACIFIC-AF Trial: Asundexian Versus Apixaban in Atrial Fibrillation</a><p>In the PACIFIC-AF clinical trial, Jonathan P. Piccini, and colleagues identified an optimal dose for, asundexian, a novel inhibitor of coagulation factor XIa (FXIa), and further compared its incidence of bleeding to that of apixaban in patients with AF. Their report, published in&nbsp;<em>The Lancet</em>, concluded that &ldquo;asundexian at doses of 20 mg and 50 mg once daily resulted in lower rates of bleeding compared with standard dosing of apixaban, with near-complete in-vivo FXIa inhibition, in patients with atrial fibrillation.</p><h2><a href="https://www.docwirenews.com/docwire-pick/bleeding-risk-with-targeted-therapies-for-immune-thrombocytopenic-purpura/">Bleeding Risk with Targeted Therapies for Immune Thrombocytopenic Purpura</a></h2><p>Investigators, led by Inbar Cohen, conducted a meta-analysis on recently-approved targeted therapies and found that &ldquo;targeted therapies for ITP increase platelet counts, decrease bleeding events, and show a trend towards lower mortality without increased toxicity,&rdquo; compared to placebo.</p><h2 class="entry-title"><a href="https://www.docwirenews.com/cardiology/got-a-fib-shed-pounds-before-treatment-to-stop-its-return/">Got A-Fib? Shed Pounds Before Treatment to Stop Its Return</a></h2><p>In a new study, patients with a-fib who were overweight or obese when they underwent ablation to correct their abnormal heart rhythm were more likely to experience a return of a-fib than folks who were not.</p><h2 class="entry-title"><a href="https://www.docwirenews.com/docwire-pick/immune-thrombocytopenia-treatment-with-rilzabrutinib/">Immune Thrombocytopenia Treatment with Rilzabrutinib</a></h2><p>According to a clinical trial published in&nbsp;<em>The New England Journal of Medicine</em>, &ldquo;rilzabrutinib showed a rapid and durable clinical activity that improved with length of treatment&rdquo; in patients with immune thrombocytopenia. The results of the trial supported the theory that the oral Bruton&rsquo;s tyrosine kinase inhibitor may support platelet count via &ldquo;decreased macrophage (Fc&gamma; receptor)-mediated platelet destruction and reduced production of pathogenic autoantibodies.&rdquo;</p><h2 class="entry-title"><a href="https://www.docwirenews.com/docwire-pick/describing-antinuclear-antibody-positive-primary-immune-thrombocytopenia/">Describing Antinuclear Antibody-Positive Primary Immune Thrombocytopenia</a></h2><p>In a retrospective study and meta-analysis published in&nbsp;<em>Lupus Science &amp; Medicine</em>, researchers sought to elucidate the risk of connective tissue diseases (CTDs) in antinuclear antibody (ANA)-positive patients with immune thrombocytopenia (ITP). According to lead authors Yuan Liu, Shiju Chen, and Guomei Yang, their analyses suggested that &ldquo;ANA-positive primary ITP is a clinical entity distinct from other primary ITPs and is associated with increased risk of developing CTDs, especially systemic lupus erythematosus (SLE).&rdquo;</p><h2><a href="https://www.docwirenews.com/docwire-pick/bleeding-risk-with-targeted-therapies-for-immune-thrombocytopenic-purpura/">Bleeding Risk with Targeted Therapies for Immune Thrombocytopenic Purpura</a></h2><p>Investigators, led by Inbar Cohen, conducted a meta-analysis on recently-approved targeted therapies and found that &ldquo;targeted therapies for ITP increase platelet counts, decrease bleeding events, and show a trend towards lower mortality without increased toxicity,&rdquo; compared to placebo.</p><h2><a href="https://www.docwirenews.com/docwire-pick/all-trans-retinoic-acid-with-high-dose-dexamethasone-in-immune-thrombocytopenia/">All-Trans Retinoic Acid with High-Dose Dexamethasone in Immune Thrombocytopenia</a></h2><p>In an article published in&nbsp;<em>The Lancet Haematology</em>, investigators showed that &ldquo;the combination of all-trans retinoic acid and high-dose dexamethasone was safe and active in newly diagnosed patients with primary immune thrombocytopenia, providing a sustained response,&rdquo; supporting it as a potentially more effectiveness first-line treatment than dexamethasone alone for patients with immune thrombocytopenia.</p><h2><a href="https://www.docwirenews.com/pad-knowledge-hub/pad-knowledge-hub-picks/drug-coated-balloon-for-small-coronary-artery-disease-treatment/">Drug-Coated Balloon for Small Coronary Artery Disease Treatment</a></h2><p>In the BASKET-SMALL 2 randomized controlled trial, researchers compared the effect of a drug-coated balloon (DCB) against drug-eluting stents (DES) in patients with&nbsp;<a href="https://www.heart.org/en/health-topics/heart-attack/angina-chest-pain/coronary-microvascular-disease-mvd">small coronary artery disease</a>, either with or without high-bleeding risk (HBR), undergoing percutaneous coronary intervention. According to the article in&nbsp;<em>Circulation: Cardiovascular Interventions</em>, &ldquo;DCBs were similarly safe and effective as current-generation DES in the treatment of coronary arteries &lt;3 mm, regardless of bleeding risk.&rdquo;</p><p>&nbsp;</p></h2>


Sara Nunnery, MD, MSCI

Reclassifying HER2: What Oncologists Need to Know About HER2-Low and -Ultralow Breast Cancer

HER2 Breast Cancer

Jeffrey Perl, MD

Joel M. Topf, MD, FACP

Thoughts From the 2025 Lazarus Award Winner

NKF Spring Clinical Meetings 2025

Brandon Twyford

DESTINY-Breast09 Demonstrates First-Line Superiority of Enhertu Plus Pertuzumab in HER2-Positive Metastatic Breast Cancer

Latest News

Cardiology Round-Up: PACIFIC-AF Trial, Immune Thrombocytopenia; and More

Cardiology

PACIFIC-AF Trial: Asundexian Versus Apixaban in Atrial Fibrillation
 ...

About Us

Editorial Policy

Advertising

Contact Us

eNewsletters

Contribute

Career Center

MashupMD

Blood Cancers Today

Cancer Nursing Today

GU Oncology Now

Urban Health Today

Bile Duct Cancer

Colorectal Cancer

Gastroesophageal Cancer

Gastric Cancer

GEP-NETs

GIST

Liver Cancer

Pancreatic Cancer

GI Oncology Now

Anemia

Deep Vein Thrombosis

Essential Thrombocythemia

Hemophilia

Immune Thrombocytopenic Purpura

Myelodysplastic Syndromes

Myelofibrosis

Myeloproliferative Neoplasms

Polycythemia Vera

Pulmonary Embolism

Sickle Cell Disease

Thrombocytopenia

Thrombophilia

Thrombosis

Thrombotic Thrombocytopenic Purpura

Venous Thromboembolism

von Willebrand Disease

Heme Today

Acute Kidney Injury

ADPKD

Anemia and Kidney Disease

Chronic Kidney Disease

COVID-19 and Kidney Disease

Diabetes and Hypertension

End-Stage Renal Disease

Gout

Hyperkalemia

IgAN

Kidney Transplantation

Metabolic Acidosis

Nephrology Times

HR Breast Cancer

Triple-Negative Breast Cancer

Genetics & Breast Cancer

Breast Cancers Today

Atherosclerotic Disease

Atrial Fibrillation

Heart Failure

Hypertension

Interventional Cardiology

Lipid Management

Practice Tips With Dr. Lichaa

Preventive Cardiology

Stroke

Breast Cancer

Gynecologic Cancer

Head and Neck Cancer

Skin Cancer

Oncology

Sleep

Urology

Diabetes

Ophthalmology

— Demodex Blepharitis

Neurology

Rheumatology

Gastroenterology

Pulmonology

Infectious Diseases

— HIV

Health and Wellness

Lupus

Future of Medicine

Orthopedics

Pharmacology

Career News

More

Conferences

CardioNerds

The Sleep Source With Dr. Morse

Rheumatology Rounds With Dr. Maheswaranathan

Partners

Expert Interviews

Subscribe